FDA Approves Early Access to Breakthrough Pancreatic Cancer Drug, First RAS Inhibitor Shows Promise
The FDA approves expanded access to daraxonrasib, the first RAS-targeting inhibitor for pancreatic cancer, which has shown promise in extending survival for metastatic patients in clinical trials.